unoprostone isopropyl

Ligand id: 8282

Name: unoprostone isopropyl

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: unoprostone isopropyl

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 17
Topological polar surface area 83.83
Molecular weight 424.32
XLogP 5.39
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

References
1. Bazan NG. (2006)
The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling.
Cell. Mol. Neurobiol., 26 (4-6): 901-13. [PMID:16897369]
2. Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R. (2007)
Cellular and molecular effects of unoprostone as a BK channel activator.
Biochim. Biophys. Acta, 1768 (5): 1083-92. [PMID:17307133]
3. Harms NV, Toris CB. (2013)
Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.
Expert Opin Pharmacother, 14 (1): 105-13. [PMID:23199345]
4. Sharif NA, Kelly CR, Crider JY. (2003)
Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Invest. Ophthalmol. Vis. Sci., 44 (2): 715-21. [PMID:12556403]
5. Tawada A, Sugawara T, Ogata K, Hagiwara A, Yamamoto S. (2013)
Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa.
Indian J Ophthalmol, 61 (3): 95-9. [PMID:23514642]
6. Tsuruma K, Tanaka Y, Shimazawa M, Mashima Y, Hara H. (2011)
Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels.
Mol. Vis., 17: 3556-65. [PMID:22219651]
7. Yamamoto S, Sugawara T, Murakami A, Nakazawa M, Nao-I N, Machida S, Wada Y, Mashima Y, Myake Y. (2012)
Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study.
Ophthalmol Ther, 1 (1): 5. [PMID:25135585]